SCHEMBL22021563

SCHEMBL22021563

CCn1nc(S(C)(=N)=O)cc1CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24978547 0.82 CA1 (0.35) —
SCHEMBL22021557 0.76 — —
SCHEMBL15746137 0.70 GAA (0.42) —
SCHEMBL21963205 0.66 CA1 (0.35) —
SCHEMBL20073784 0.66 HTT (0.43) —
SCHEMBL13184397 0.65 MPO (0.43) —
SCHEMBL22412844 0.64 MAPT (0.44) —
SCHEMBL20754689 0.64 CA2 (0.32) —
SCHEMBL22021565 0.63 ADORA2A (0.30) —
SCHEMBL20757369 0.62 TMEM97 (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020102096-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY NOVARTIS INFLAMMASOME RESEARCH, INC. (US) 2020-05-22 — — WO disclosed
Send feedback